<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1506222194
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        GABEX 300 mg capsule
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PREGABALIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        300
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Controlled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        129.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory  Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N03AX16
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Gabex&trade; belongs to a group of medicines used to treat epilepsy,<br />neuropathic pain and Generalised Anxiety Disorder (GAD) in adults.<br />Peripheral and central neuropathic pain:<br />Gabex&trade; is used to treat long lasting pain caused by damage to the nerves.<br />A variety of diseases can cause peripheral neuropathic pain, such as<br />diabetes. Pain sensations may be described as hot, burning, throbbing,<br />shooting, stabbing, sharp, cramping, aching, tingling, numbness, pins and<br />needles. Peripheral and central neuropathic pain may also be associated<br />with mood changes, sleep disturbance, fatigue (tiredness), and can have an<br />impact on physical and social functioning and overall quality of life.<br />Epilepsy:<br />Gabex&trade; is used to treat a certain form of epilepsy (partial seizures with or<br />without secondary generalisation) in adults. Your doctor will prescribe<br />Gabex&trade; for you to help treat your epilepsy when your current treatment is<br />not controlling your condition. You should take<br />Gabex&trade; in addition to your current treatment. Gabex&trade; is not intended to be<br />used alone, but should always be used in combination with other<br />anti-epileptic treatment.<br />Generalised Anxiety Disorder:<br />Gabex&trade; is used to treat Generalised Anxiety Disorder (GAD). The<br />symptoms of GAD are prolonged excessive anxiety and worry that are<br />difficult to control. GAD can also cause restlessness or feeling keyed up or<br />on edge, being easily fatigued (tired), having difficulty concentrating or<br />mind going blank, feeling irritable, having muscle tension or sleep<br />disturbance. This is different to the stresses and strains of everyday life.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Gabex&trade;<br />If you are allergic to pregabalin or any of the other ingredients of this<br />medicine (listed in section 6).<br />Warnings and Precautions<br />&bull; Some patients taking pregabalin have reported symptoms suggesting an<br />allergic reaction. These symptoms include swelling of the face, lips,<br />tongue, and throat, as well as diffuse skin rash. Should you experience any<br />of these reactions, you should contact your physician immediately.<br />&bull; Pregabalin has been associated with dizziness and somnolence, which<br />could increase the occurrence of accidental injury (fall) in elderly patients.<br />Therefore, you should be careful until you are used to any effect the<br />medicine might have.<br />&bull; Gabex&trade; may cause blurring or loss of vision, or other changes in<br />eyesight, many of which are temporary. You should immediately tell your<br />doctor if you experience any changes in your vision.<br />&bull; Some patients with diabetes who gain weight while taking pregabalin<br />may need an alteration in their diabetic medicines.<br />&bull; Certain side effects may be more common, such as sleepiness, because<br />patients with spinal cord injury may be taking other medicines to treat, for<br />example, pain or spasticity, that have similar side effects to Pregabalin and<br />the severity of these effects may be increased when taken together.<br />&bull; There have been reports of heart failure in some patients when taking<br />pregabalin these patients were mostly elderly with cardiovascular<br />conditions. Before taking this medicine you should tell your doctor if<br />you have a history of heart disease.<br />&bull; There have been reports of kidney failure in some patients when taking<br />pregabalin. If while taking Gabex&trade; you notice decreased urination, you<br />should tell your doctor as stopping the medicine may improve this.<br />&bull; A small number of people being treated with anti-epileptics such as<br />Gabex&trade; have had thoughts of harming or killing themselves. If at any time<br />you have these thoughts, immediately contact your doctor.<br />&bull; When Gabex&trade; is taken with other medicines that may cause constipation<br />(such as some types of pain medicines) it is possible that gastrointestinal<br />problems may occur (e.g., constipation, blocked or paralysed bowel). Tell<br />your doctor if you experience constipation, especially if you are prone to<br />this problem.<br />&bull; Before taking this medicine you should tell your doctor if you have a<br />history of alcoholism or drug dependence. &bull; There have been reports of convulsions when taking pregabalin or<br />shortly after stopping pregabalin. If you experience a convulsion, contact<br />your doctor immediately.<br />&bull; There have been reports of reduction in brain function (encephalopathy)<br />in some patients taking pregabalin when they have other conditions. Tell<br />your doctor if you have a history of any serious medical conditions,<br />including liver or kidney disease.<br />Children and adolescents<br />The safety and efficacy in children and adolescents (under 18 years of age)<br />has not been established and therefore, pregabalin should not be used in<br />this age group.<br />Other medicines and Gabex&trade;<br />Tell your doctor or pharmacist if you are taking, have recently taken or<br />might take any other medicines.<br />Gabex&trade; and certain other medicines may influence each other<br />(interaction). When taken with certain other medicines, Gabex&trade; may<br />potentiate the side effects seen with these medicines, including respiratory<br />failure and coma. The degree of dizziness, sleepiness and decreased<br />concentration may be increased if Gabex&trade; is taken together with medicinal<br />products containing:<br />Oxycodone - (used as a pain-killer)<br />Lorazepam - (used for treating anxiety)<br />Alcohol<br />Gabex&trade; may be taken with oral contraceptives.<br />Gabex&trade; with food, drink and alcohol<br />Gabex&trade; capsules may be taken with or without food.<br />It is advised not to drink alcohol while taking Gabex&trade;.<br />Pregnancy and breast-feeding<br />Gabex&trade; should not be taken during pregnancy, unless you are told<br />otherwise by your doctor. Effective contraception must be used by women<br />of child-bearing potential. If you are pregnant or breast-feeding, think you<br />may be pregnant or are planning to have a baby, ask your doctor or<br />pharmacist for advice before taking this medicine.<br />It is not recommended to breast-feed your baby while using Gabex&trade; as it<br />is not known if Gabex&trade; may be found in breast milk. Ask your doctor or<br />pharmacist for advice before taking any medicine while breast-feeding.<br />Driving and using machines<br />Gabex&trade; may produce dizziness, sleepiness and decreased concentration.<br />You should not drive, operate complex machinery or engage in other<br />potentially hazardous activities until you know whether this medicine<br />affects your ability to perform these activities.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with<br />your doctor or pharmacist if you are not sure.<br />Your doctor will determine what dose is appropriate for you. Gabex&trade; is for<br />oral use only.<br />Peripheral and central neuropathic pain, epilepsy or Generalised<br />Anxiety Disorder:<br />&bull; Take the number of capsules as instructed by your doctor.<br />&bull; The dose, which has been adjusted for you and your condition, will<br />generally be between 150 mg and 600 mg each day.<br />&bull; Your doctor will tell you to take Gabex&trade; either twice or three times a<br />day. For twice a day take Gabex&trade; once in the morning and once in the<br />evening, at about the same time each day. For three times a day take<br />Gabex&trade; once in the morning, once in the afternoon and once in the<br />evening, at about the same time each day.<br />If you are an elderly patient (over 65 years of age), you should take<br />Gabex&trade; normally except if you have problems with your kidneys.<br />Your doctor may prescribe a different dosing schedule and/or dose if you<br />have problems with your kidneys.<br />Swallow the capsule whole with water.<br />Continue taking Gabex&trade; until your doctor tells you to stop.<br />If you take more Gabex&trade; than you should<br />Call your doctor or go to the nearest hospital emergency unit immediately.<br />Take your pack of Gabex&trade; capsules with you. You may feel sleepy,<br />confused, agitated, or restless as a result of taking more Gabex&trade; than you<br />should.<br />If you forget to take Gabex&trade;<br />It is important to take your Gabex&trade; capsules regularly at the same time<br />each day. If you forget to take a dose, take it as soon as you remember<br />unless it is time for your next dose. In that case, just carry on with the next<br />dose as normal. Do not take a double dose to make up for a forgotten dose.<br />If you stop taking Gabex&trade;<br />Do not stop taking Gabex&trade; unless your doctor tells you to.<br />If your treatment is stopped it should be done gradually over a minimum<br />of 1 week.<br />After stopping long and short-term Gabex&trade; treatment, you need to know<br />that you may experience certain side effects. These include, trouble<br />sleeping, headache, nausea, feeling anxious, diarrhoea, flu- like symptoms,<br />convulsions, nervousness, depression, pain, sweating, and dizziness. These<br />symptoms may occur more commonly or severely if you have been taking<br />Gabex&trade; for a longer period of time.<br />If you have any further questions on the use of this medicine, ask your<br />doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not<br />everybody gets them.<br />Very common: may affect more than 1 in 10 people<br />Dizziness, drowsiness, headache.<br />Common: may affect up to 1 in 10 people<br />&bull; Increased appetite.<br />&bull; Feeling of elation, confusion, disorientation, changes in sexual interest,<br />irritability.<br />&bull; Disturbance in attention, clumsiness, memory impairment, loss of<br />memory, tremor, difficulty with speaking, tingling feeling, numbness,<br />sedation, lethargy, insomnia, fatigue, feeling abnormal.<br />&bull; Blurred vision, double vision.<br />&bull; Vertigo, problems with balance, fall.<br />&bull; Dry mouth, constipation, vomiting, flatulence, diarrhoea, nausea,<br />swollen abdomen.<br />&bull; Difficulties with erection.<br />&bull; Swelling of the body including extremities.<br />&bull; Feeling drunk, abnormal style of walking.<br />&bull; Weight gain.<br />&bull; Muscle cramp, joint pain, back pain, pain in limb.<br />&bull; Sore throat.<br />Uncommon: may affect up to 1 in 100 people<br />&bull; Loss of appetite, weight loss, low blood sugar, high blood sugar.<br />&bull; Change in perception of self, restlessness, depression, agitation, mood<br />swings, difficulty finding words, hallucinations, abnormal dreams, panic<br />attacks, apathy, aggression, elevated mood, mental impairment, difficulty<br />with thinking, problems with sexual functioning including inability to<br />achieve a sexual climax, delayed ejaculation.<br />&bull; Changes in eyesight, unusual eye movement, changes in vision<br />including tunnel vision, flashes of light, jerky movements, reduced<br />reflexes, increased activity, dizziness on standing, sensitive skin, loss of<br />taste, burning sensation, tremor on movement, loss of consciousness,<br />fainting, increased sensitivity to noise, feeling unwell.<br />&bull; Dry eyes, eye swelling, eye pain, weak eyes, watery eyes, eye irritation.<br />&bull; Heart rhythm disturbances, increased heart rate, low blood pressure,<br />high blood pressure, changes in heart beat, heart failure.<br />&bull; Flushing, hot flushes.<br />&bull; Difficulty breathing, dry nose, nasal congestion.<br />&bull; Increased saliva production, heartburn, numb around mouth.<br />&bull; Sweating, rash, chills, fever.<br />&bull; Muscle twitching, joint swelling, muscle stiffness, pain including<br />muscle pain,neck pain.<br />&bull; Breast pain.<br />&bull; Difficulty with or painful urination, incontinence.<br />&bull; Weakness, fall, thirst, chest tightness.<br />&bull; Hypersensitivity, swollen face, itchiness, hives, runny nose, nose bleed,<br />cough, snoring.<br />&bull; Painful menstrual periods.<br />&bull; Coldness of hands and feet.<br />Rare: may affect up to 1 in 1,000 people<br />&bull; Abnormal sense of smell, swinging vision, altered perception of depth,<br />visual brightness, vision loss.<br />&bull; Dilated pupils, cross eyes.<br />&bull; Cold sweat, tightness of the throat, swollen tongue.<br />&bull; Inflammation of the pancreas.<br />&bull; Difficulty in swallowing.<br />&bull; Slow or reduced movement of the body.<br />&bull; Difficulty with writing properly. Increased fluid in the abdomen.<br />&bull; Fluid in the lungs<br />&bull; Convulsions<br />&bull; Changes in the recording of electrical changes (ECG) in the heart which<br />correspond to heart rhythm disturbances<br />&bull; Muscle damage.Breast discharge, abnormal breast growth, breast<br />growth in males.<br />&bull; Interrupted menstrual periods.<br />&bull; Kidney failure, reduced urine volume, urinary retention.<br />&bull; Decrease in white blood cell count.<br />&bull; Inappropriate behaviour.<br />&bull; Allergic reactions (which may include difficulty breathing, inflammation<br />of the eyes (keratitis) and a serious skin reaction characterized by rash,<br />blisters, peeling skin and pain).<br />If you experience swollen face or tongue or if your skin turns red and<br />starts to blister or peel you should seek immediate medical advice.<br />Certain side effects may be more common, such as sleepiness, because<br />patients with spinal cord injury may be taking other medicines to treat, for<br />example, pain or spasticity, that have similar side effects to Pregabalin<br />and the severity of these effects may be increased when taken together.<br />If you get any side effects, talk to your doctor or pharmacist. This<br />includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep out of the reach and sight of children.<br />&bull; Do not store above 30 &ordm;C.<br />&bull; Store in the original package. Store in dry place.<br />&bull; Do not use this medicine after the expiry date which is stated on the<br />carton.<br />&bull; Medicines should not be disposed of via wastewater or household waste.<br />Ask your pharmacist how to dispose of medicines no longer required.<br />These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is pregabalin.<br />Each hard capsule contains either 75mg, 150mg or 300mg pregabalin.<br />The other ingredients are:<br />Pregelatinized starch, Talc, Gelatin, Sodium lauryl sulphate and Titanium<br />dioxide.<br />Gabex&trade; 75mg capsules also contain brilliant blue (FD&amp;C blue no.1).<br />Gabex&trade; 300mg capsules also contain iron oxide red.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Gabex™ capsules 75mg :
White and blue hard gelatin capsule, marked “Jamjoom” on the cap and
“PGN 75” on the body with black ink.
Gabex™ capsules 150mg :
White hard gelatin capsule, marked “Jamjoom” on the cap and “PGN 150”
on the body with black ink.
Gabex™ capsules 300mg :
White and dark brown hard gelatin capsule, marked “Jamjoom” on the cap
and “PGN 300” on the body with black ink.
Gabex™ 75mg capsules, pack of 30 capsules.
Gabex™ 150mg capsules, pack of 30 capsules.
Gabex™ 300mg capsules, pack of 30 capsules.
Not all packs may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder and Manufacturer<br />Jamjoom Pharmaceuticals Co., Ltd.,<br />Jeddah, Saudi Arabia.<br />Tel: +966-12-6081111<br />Fax: +966-12-6081222.<br />Website: www.jamjoompharma.com<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />- The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222,<br />Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last reviewed in 05/2015
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>۱. ما هو جابكس&nbsp;وما هي دواعي استعماله.<br />ينتمي إلى مجموعة من الأدوية المستخدمة لعلاج الصرع، ألم الإعتلال &trade; جابكس<br />في البالغين. (GAD) العصبي واضطراب القلق العام<br />ألم اعتلال الأعصاب الطرفية و المركزية:<br />لعلاج الألم طويل الأمد الناجم عن تلف الأعصاب. هنالك &trade; يستخدم جابكس<br />مجموعة متنوعة من الأمراض يمكن أن تسبب ألم اعتلال الأعصاب الطرفية، مثل<br />مرض السكري.<br />وقد يوصف الإحساس بالألم بأنه إحساس بالسخونة أو بألم حارق<br />أو نابض أو مفاجئ أو واخز أو حاد أو مصحوب بتقلصات أو أوجاع أو تنميل أو<br />خدر أو وخز كوخز الدبابيس و الإبر. قد يكون ألم اعتلال الأعصاب الطرفية<br />والمركزية مصحوباً بتقلباتٍ في المزاج و اضطراب النوم والإرهاق (التعب)، وقد<br />يكون له تأثير على الأداء البدني والاجتماعي وعلى نوعية الحياة عامة.<br />الصرع:<br />لعلاج شكل معين من الصرع (النوبات الجزئية المصحوبة أو &trade; يستخدم جابكس<br />للمساعدة &trade; غير المصحوبة بتعمٌم ثانوي) في البالغين. وسيصف لك الطبيب جابكس<br />في علاج الصرع الذي تعاني منه عندما يكون علاجك الحالي لا يسيطر على<br />ليس مخصصاً &trade; بجانب علاجك الحالي. جابكس &trade; حالتك. وينبغي تناول جابكس<br />للإستخدام بمفرده، وينبغي دائماً أن يستخدم بالتزامن مع غيره من العلاجات<br />المضادة للصرع.<br />اضطراب القلق العام:<br />و تتمثل أعراض .(GAD) لعلاج اضطراب القلق العام &trade; يستخدم جابكس<br />اضطراب القلق العام في التوتر و القلق المستمر الزائد والذين يصعب التحكم بهما.<br />قد يسبب اضطراب القلق العام أيضا التململ أو الشعور بالإنفعال أوالعصبية، أو<br />الشعور بالإرهاق (التعب) بسرعة أو وجود صعوبة في التركيز أو توقف العقل عن<br />العمل، أو الشعور بالإنزعاج أو حدوث توتر عضلي أو اضطراب النوم. يختلف<br />هذا عن الضغوط النفسية و إجهادات الحياة اليومية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>۲. ما يتعين عليك معرفته قبل تناول جابكس<br />&trade; موانع استعمال جابكس<br />&bull; إذا كان لديك حساسية تجاه بريجابالين أو أى من المكونات الأخرى لهذا الدواء<br />.( (المذكورة فى القسم رقم ٦<br />تحذيرات و احتياطات<br />&bull; أبلغ بعض المرضى الذين تناولوا بريجابالين عن حدوث أعراض ترجح حدوث<br />تفاعل حساسية. تتضمن هذة الاعراض تورم الوجه، الشفتين، اللسان، الحلق، إلى<br />جانب طفح جلدي منتشر. إذا واجهت أي من هذه التفاعلات، ينبغى عليك الاتصال<br />بطبيبك على الفور.<br />&bull; ارتبط إستخدام بريجابالين بحدوث الدوار و النعاس، و الذي يمكن أن يزيد من<br />حدوث الإصابة بحوادث (السقوط) في المرضى المسنين. لذا، ينبغي عليك توخي<br />الحذر حتى تعتاد علي أي تأثير قد يسببه الدواء.<br />عدم وضوح أو فقدان الرؤية، أو تغييرات أخرى في الرؤية، &trade; &bull; قد يسبب جابكس<br />والتى يكون العديد منها مؤقتاً. يجب أن تخبر طبيبك علي الفور إذا أصبت بأي<br />تغييرات في الرؤية.<br />&bull; قد يحتاج بعض مرضى السكري الذين ازداد وزنهم أثناء إستخدام بريجابالين إلى<br />تغيير أدوية علاج السكري الخاصة بهم.<br />&bull; قد تكون بعض الآثار الجانبية أكثر شيوعا، مثل النعاس، وذلك لأن المرضى<br />الذين يعانون من اصابات الحبل الشوكي قد يتناولوا أدوية أخرى لعلاج، على سبيل<br />المثال، الألم أو فرط التوتر التشنجي، و هذه الأدوية لها آثار جانبية مشابهة<br />لبريجابالين وحدة هذه الآثارالجانبية قد تزداد عند تناول هذه الأدوية معاً.<br />&bull; كانت هناك تقارير حول حدوث الفشل القلبي في بعض المرضى عند تناولهم<br />بريجابالين؛ كان معظم هؤلاء المرضى من المسنين و يعانون من امراض قلبية<br />وعائية. قبل تناول هذا الدواء عليك أن تخبر طبيبك إذا كان لديك تاريخ للإصابة<br />بأمراض القلب.<br />&bull; تم الإبلاغ عن حدوث حالات فشل كلوي في بعض المرضى عند تناولهم<br />شح البول، يجب عليك إخبار الطبيب &trade; بريجابالين. إذا لاحظت أثناء تناول جابكس<br />حيث أن التوقف عن تناول الدواء قد يحسن من هذه الحالة.<br />&bull; إنتابت عدد قليلاً من المرضى الخاضعين للعلاج بأدوية مضادات الصرع مثل<br />أفكار إلحاق الأذى بأنفسهم أو الإنتحار. إذا ما أنتابتك مثل هذه الأفكار في &trade; جابكس<br />أي وقت، فاتصل بطبيبك على الفور.<br />بالتزامن مع أدوية أخرى التي قد تسبب الإمساك (مثل بعض &trade; &bull; عند تناول جابكس<br />أنواع الأدوية المسكنة للآلام) فمن المحتمل حدوث مشاكل الجهاز الهضمي (مثل<br />الإمساك، إحصار أو شلل الأمعاء). أخبر طبيبك إذا أصبت بالإمساك، خاصة إذا<br />كنت عرضه للإصابة بمثل هذه المشكلة.<br />&bull; قبل تناول هذا الدواء ينبغي عليك إخبار طبيبك إذا كان لديك تاريخ لإدمان<br />الكحوليات أو الاعتمادية علي العقاقير. (لا تتناول أكثر من الجرعة الموصوفه).<br />&bull; تم الإبلاغ عن حدوث اختلاجات أثناء فترة تناول بريجابالين أو بعد فترة قصيرة<br />من التوقف عن تناول بريجابالين. إذا أصبت باختلاجات، فاتصل بطبيبك فوراً.<br />&bull; كانت هناك تقارير عن انخفاض في وظيفة الدماغ (اعتلال الدماغ) في بعض<br />المرضى الذين يتناولون بريجابالين عندما يكون لديهم حالات مرضية أخرى. أخبر<br />طبيبك إذا كان لديك تاريخ منالإصابة بأي من الحالات الطبية الخطيرة، بما في ذلك<br />أمراض الكبد أو الكلى.<br />الأطفال والمراهقين<br />لم تثبت مأمونية و فعالية الدواء في الأطفال والمراهقين (تحت سن ۱۸ عام) ولذا،<br />ينبغي عدم إستخدام بريجابالين مع هذه الفئة العمرية.<br />مع أدوية أخرى &trade; التداخلات الدوائية من تناول جابكس<br />أخبر طبيبك أو الصيدلي إذا كنت تتناول، تناولت مؤخراً أو قد تتناول أي أدوية<br />أخرى.<br />وبعض الأدوية الأخرى علي بعضها البعض (التفاعل). عند &trade; قد يؤثر جابكس<br />من الآثار الجانبية الملاحظة عند &trade; تناوله مع بعض الأدوية، قد يزيد جابكس<br />إستعمال هذه الأدوية، بما في ذلك الفشل التنفسي والغيبوبة. قد تزداد درجة الدوار،<br />جنبا إلى جنب مع المنتجات &trade; النعاس وانخفاض التركيز إذا تم تناول جابكس<br />الدوائية التي تحتوي على:<br />أوكسيكودون - (يستخدم كمسكن للألم)<br />لورازيبام - (يستخدم لعلاج القلق)<br />الكحول<br />مع وسائل منع الحمل الفموية. &trade; يمكن تناول جابكس<br />مع الطعام والشراب والكحوليات &trade; تناول جابكس<br />مع الطعام أو بدونه. &trade; يمكن تناول كبسولات جابكس<br />.&trade; ينصح بعدم تناول المشروبات الكحولية أثناء تناول جابكس<br />الحمل والرضاعة الطبيعية<br />أثناء الحمل، ما لم يخبرك طبيبك بخلاف ذلك . &trade; لا ينبغي تناول جابكس<br />يجب على السيدات القادرات على الإنجاب إستخدام وسيلة فعالة لمنع الحمل.<br />إذا كنت حاملاً أو ترضعين رضاعة طبيعية، أو تعتقدين أنك ربما تكونين حاملاً أو<br />تخططين للحمل، يجب إستشارة طبيبك أو الصيدلي قبل تناول هذا الدواء.<br />نظراً لعدم &trade; لا يوصى بارضاع طفلك رضاعة طبيعية أثناء استخدامك جابكس<br />يفرز في لبن الثدي. &trade; معرفة إذا ما كان جابكس<br />إستشيري طبيبك أو الصيدلي قبل تناول أي دواء و أنت ترضعين.<br />على القيادة و إستخدام الآلات &trade; تأثير جابكس<br />في حدوث دوار، نعاس وانخفاض التركيز. ينبغي عليك تجنب &trade; قد يتسبب جابكس<br />القيادة أو تشغيل الآلات المعقدة أو المشاركة في أنشطة ذات خطورة محتملة حتى<br />تتأكد مما إذا كان هذا الدواء يؤثر على قدرتك على القيام بهذه الأنشطة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>۳. طريقة تناول جابكس<br />قم دائما بتناول هذا الدواء تماما كما أخبرك طبيبك. إستشر طبيبك أو الصيدلى إذا<br />كنت غير متأكد. سيحدد طبيبك الجرعة المناسبة لك.<br />هو للاستخدام عن طريق الفم فقط. &trade; جابكس<br />ألم الإعتلال العصبي الطرفي و المركزي، الصرع، إضطراب القلق العام:<br />&bull; تناول عدد الكبسولات وفقا لتعليمات طبيبك.<br />&bull; ستتراوح الجرعة التي تم تعديلها من أجلك ووفق حالتك، بشكل عام بين<br />۱٥۰ ملجم و ٦۰۰ ملجم كل يوم.<br />إما مرتين أو ثلاث مرات في اليوم. في حال &trade; &bull; طبيبك سيخبرك أن تتناول جابكس<br />مرة في الصباح ومرة في المساء، في &trade; وصف الدواء مرتين يومياً فتناول جابكس<br />نفس الوقت تقريبا كل يوم. في حال وصف الدواء لثلاث مرات يومياً فتناول<br />مرة في الصباح، ومرة بعد الظهر ومرة في المساء، في نفس الوقت &trade; جابكس<br />تقريبا كل يوم.<br />&trade; إذا كنت مريض مسناً (عمرك أكبر من ٦٥ عاماً)، فيمكنك أن تتناول جابكس<br />عاديا إلا إذا كنت تعاني مشاكل في الكلى.<br />قد يصف لك طبيبك جرعة و/أو نظام جرعات مختلف إذا كان لديك مشاكل في<br />الكلى.<br />قم بابتلاع الكبسولة كاملة مع الماء.<br />حتى يخبرك طبيبك بالتوقف. &trade; إستمر في تناول جابكس<br />عند تناول جرعة زائدة:<br />اتصل بطبيبك أو أذهب إلى وحدة الطوارئ في أقرب مستشفى على الفور. قم بأخذ<br />الخاصة بك معك. قد تشعر بالنعاس، التشويش، الهياج، أو &trade; علبة كبسولات جابكس<br />.&trade; التململ نتيجة لتناول جرعة زائدة من جابكس<br />:&trade; إذا نسيت أن تتناول جابكس<br />بشكل منتظم في نفس الوقت كل يوم. إذا &trade; من المهم أن تتناول كبسولات جابكس<br />نسيت تناول إحدى الجرعات، فتناولها بمجرد أن تتذكر إلا إذا كان الوقت قد حان<br />لتناول جرعتك التالية. في هذه الحالة، استمر فقط في الجرعة التالية كالمعتاد. لا<br />تتناول جرعة مضاعفة لتعويض الجرعة المنسية.<br />:&trade; إذا توقفت عن تناول جابكس<br />ما لم يخبرك طبيبك بهذا. إذا ما استلزم الأمر إيقاف &trade; لا تتوقف عن تناول جابكس<br />علاجك يجب أن يتم ذلك تدريجيا على مدار أسبوع واحد علي الأقل.<br />طويل أو قصير الأمد، فأنت بحاجة إلى معرفة أنك قد &trade; بعد إيقاف العلاج بجابكس<br />تواجه بعض الآثار الجانبية. وتشمل هذه الآثار الجانبية، اضطرابات النوم، صداع،<br />غثيان، شعور بالقلق، إسهال، أعراض شبيهة بأعراض الإنفلونزا، إختلاجات،<br />عصبية، اكتئاب، ألم، تعرق و دوار. قد تحدث هذه الأعراض بصورة أكثر شيوعاً<br />لمدة طويلة. &trade; أو شدة إذا كنت قد تناولت جابكس<br />إذا كان لديك أي أسئلة أخرى عن استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>٤. الآثار الجانبية المحتملة<br />كما هو الحال بالنسبة لجميع الأدوية ، قد يسبب هذا الدواء آثاراً جانبية، غير أنها لا<br />تحدث للجميع.<br />آثار جانبية شائعة جداً: قد تؤثر علي أكثر من شخص واحد من كل ۱۰ أشخاص<br />دوار، نعاس، صداع.<br />آثار جانبية شائعة: قد تؤثر على ما يصل إلى شخص واحد من كل ۱۰ أشخاص<br />&bull; ازدياد الشهية للطعام.<br />&bull; شعور بالانتشاء، الارتباك، التوهان، تغير في الاهتمام الجنسي، التهيج.<br />&bull; تشوش في الانتباه، الخرق، ضعف الذاكرة، فقدان الذاكرة، رعاش، صعوبة مع<br />التحدث، شعور بوخز، خدر، تخدير، خمول، أرق، تعب و شعور غير طبيعي.<br />&bull; تغيم الرؤية، ازدواج الرؤية.<br />&bull; دوار، مشاكلات في الاتزان، سقوط.<br />&bull; جفاف في الفم، إمساك، قيء، امتلاء البطن بالغازات، إسهال، غثيان، وانتفاخ<br />البطن.<br />&bull; صعوبة الانتصاب.<br />&bull; تورم الجسم بما في ذلك الأطراف.<br />&bull; الشعور بالثمل، طريقة غير طبيعية من المشي.<br />&bull; زيادة الوزن.<br />&bull; تشنج العضلات، آلام المفاصل، آلام الظهر، آلام في الأطراف.<br />&bull; التهاب الحلق.<br />آثار جانبية غير شائعة: قد تؤثر علي أكثر من شخص واحد من كل ۱۰۰ شخص<br />&bull; فقدان الشهية، فقدان الوزن، إنخفاض السكر في الدم، ارتفاع السكر في الدم.<br />&bull; تغيير في التصور عن الذات، تململ، اكتئاب، هياج، تغيرات المزاج، صعوبة<br />إيجاد الكلمات، هلوسة، أحلام غير طبيعية، نوبات الهلع، لامبالاة، عدوانية، مزاج<br />مرتفع ، ضعف عقلي، صعوبة التفكير، مشاكل مع الأداء الجنسي بما في ذلك عدم<br />القدرة على الوصول إلى هزة الجماع و تأخر القذف.<br />&bull; تغيرات في الرؤية، حركة العين غير عادية، بما في ذلك تغير فى الرؤية في نفق<br />الرؤية، ومضات من الضوء، حركات تشنجية، قلة في ردود الفعل، زيادة النشاط،<br />دوار عند الوقوف، حساسية الجلد، فقدان حاسة التذوق،حرقان، رعاش عند<br />الحركة، انخفاض الوعي، إغماء، زيادة الحساسية للضوضاء، الشعور بتوعك.<br />&bull; جفاف العين، تورم العين، ألم العين، ضعف العين، عيون دامعة، تهيج العين.<br />&bull; اضطراب نظم القلب، زيادة معدل ضربات القلب، انخفاض ضغط الدم، ارتفاع<br />ضغط الدم، تغير في ضربات القلب، فشل القلب.<br />&bull; إحمرار الوجه، هبات الحرارة.<br />&bull; صعوبة التنفس، جفاف الأنف، احتقان الحلق.<br />&bull; زيادة إفراز اللعاب، حرقة في المعدة، خدر حول الفم، حمى.<br />&bull; تعرق، طفح جلدي، قشعريرة.<br />&bull; ارتعاش العضلات، تورم المفاصل، تصلب العضلات، ألم بما في ذلك ألم<br />العضلات، ألم الرقبة.<br />&bull; ألم الثدي.<br />&bull; صعوبة أو ألم في التبول، سلس البول.<br />&bull; ضعف، سقوط، عطش، ضيق الصدر.<br />&bull; فرط الحساسية، تورم الوجه، حكة، شرى، سيلان الأنف، نزيف الأنف، سعال،<br />شخير.<br />&bull; فترات حيض مؤلمة.<br />&bull; برودة في اليدين والقدمين.<br />آثار جانبية نادرة: قد تؤثر على ما يصل إلى شخص واحد من كل ۱۰۰۰ شخص<br />&bull; إحساس غير طبيعي بالشم،تأرجح الرؤية ، تغير النظرة من العمق، سطوع<br />الرؤية، فقدان الرؤية.<br />&bull; اتساع البؤبؤ، حول العينان.<br />&bull; العرق البارد، ضيق في الحلق وتورم اللسان.<br />&bull; التهاب البنكرياس.<br />&bull; صعوبة في البلع.<br />&bull; بطء أو قلة في حركة الجسم.<br />&bull; صعوبة الكتابة بطريقة صحيحة. زيادة السوائل في البطن.<br />&bull; سوائل في الرئتين.<br />&bull; تشنجات.<br />(ECG &bull; تغيرات في تسجيل التغيرات الكهربائية للقلب ( مخطط كهربية القلب<br />والتي تقابل اضطرابات نظم القلب.<br />&bull; تلف العضلات، إفرازات الثدي، نمو غير طبيعي للثدي، نمو الثدي عند الذكور.<br />&bull; تقطع الحيض.<br />&bull; فشل كلوي، انخفاض حجم البول، احتباس البول.<br />&bull; نقص في عدد خلايا الدم البيضاء.<br />&bull; سلوك غير لائق.<br />&bull; الحساسية (والتي قد تشمل صعوبة في التنفس، التهاب في العينين (التهاب<br />القرنية) و رد فعل جلدي خطير يتميز بطفح جلدي، بثور، تقشير الجلد والألم).<br />إذا واجهت تورم الوجه أو اللسان أو اذا إحمرت بشرتك وبدأت في التقرح أو<br />التقشر فإنه يجب أن تطلب المشورة الطبية فوراً.<br />قد تكون بعض الآثار الجانبية أكثر شيوعا، مثل النعاس، وذلك لأن المرضى الذين<br />يعانون من اصابة في الحبل الشوكي قد يتناولوا أدوية أخرى لعلاج، على سبيل<br />المثال، الألم أو فرط التوتر التشنجي، و هذه الأدوية لها آثار جانبية مشابهة<br />لبريجابالين وقد تزداد حدة هذه الآثار الجانبية عند تناول هذه الأدوية معاً.<br />اذا واجهت أي آثار جانبية، تحدث إلى طبيبك أو الصيدلي. وهذا يشمل أي آثار<br />جانبية محتملة غير مذكورة في هذه النشرة.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>٥. ظروف تخزين جابكس<br />&bull; يحفظ بعيداً عن متناول و مرأى الأطفال.<br />&bull; يحفظ فى درجة حرارة لا تزيد عن ۳۰ درجة مئوية.<br />&bull; يحفظ في العبوة الأصلية. يحفظ في مكان جاف.<br />&bull; لا تتناول هذا الدواء بعد انتهاء فترة الصلاحية المبينة على العبوة.<br />&bull; يجب عدم التخلص من الأدوية عبر إلقائها فى بالوعات الصرف أو فى مخلفات<br />المنزل. اسأل الصيدلي عن طريقة التخلص من الأدوية التي لم تعد بحاجة إليها.<br />ستساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>٦. معلومات إضافية.<br />&trade; ما هي مكونات كبسولات جابكس<br />المادة الفعالة هي بريجابالين.<br />تحتوي كل كبسولة جيلاتينية صلبة إما علي ۷٥ ملجم، ۱٥۰ ملجم أو ۳۰۰ ملجم<br />بريجابالين.<br />المكونات الأخرى هي:<br />نشا بريجيلاتينيزيد، تلك، جيلاتين، صوديوم لوريل سلفات و ثاني أكسيد<br />التايتانيوم.<br />أزرق FD&amp;C) ۷٥ ملجم أيضا علي أزرق لامع &trade; تحتوي كبسولات جابكس<br />( رقم 1<br />۳۰۰ ملجم أيضا علي أكسيد الحديد الأحمر. &trade; تحتوي كبسولات جابكس<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>ما هو شكل كبسولات جابكس<br />۷٥ ملجم : &trade; كبسولات جابكس<br />و مطبوع &#39;Jamjoom&#39; كبسولات جيلاتينية صلبة مطبوع على غطائها الأزرق<br />.&ldquo;PGN على جسمها الأبيض بالحبر الأسود &rdquo; 75<br />۱٥۰ ملجم : &trade; كبسولات جابكس<br />و مطبوع &#39;Jamjoom&#39; كبسولات جيلاتينية صلبة مطبوع على غطائها الأبيض<br />.&ldquo;PGN على جسمها الأبيض بالحبر الأسود &rdquo; 150<br />۳۰۰ ملجم : &trade; كبسولات جابكس<br />و مطبوع &#39;Jamjoom&#39; كبسولات جيلاتينية صلبة مطبوع على غطائها البني الغامق<br />.&ldquo;PGN على جسمها الأبيض بالحبر الأسود &rdquo; 300<br />۷٥ ملجم : عبوة تحتوى على ۳۰ كبسولة. &trade; كبسولات جابكس<br />۱٥۰ ملجم : عبوة تحتوى على ۳۰ كبسولة. &trade; كبسولات جابكس<br />۳۰۰ ملجم : عبوة تحتوى على ۳۰ كبسولة. &trade; كبسولات جابكس<br />قد لا تكون كل العبوات مطروحة بالسوق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>اسم وعنوان مالك رخصة التسويق و المصنع:<br />شركة مصنع جمجوم للأدوية المحدودة، جدة، المملكة العربية السعودية.<br />+۹٦٦-۱۲- الهاتف: ٦۰۸۱۱۱۱<br />+۹٦٦-۱۲- فاكس: ٦۰۸۱۲۲۲<br />www.jamjoompharma.com : الموقع الإلكتروني<br />للإبلاغ عن أي أثار جانبيه:<br />&bull; المملكة العربية السعودية:<br />- المركز الوطني للتيقظ و السلامة الدوائية<br />+۹٦٦-۱۱-۲۰٥- فاكس: ۷٦٦۲ o<br />للإتصال بالإدارة التنفيذية للتيقظ وإدارة الأزمات. o<br />.+۹٦٦-۱۱- هاتف: ۲۰۳۸۲۲۲۲<br />۲۳٤۰-۲۳۳٤-۲۳٥٤-۲۳٥۳-۲۳٥٦- تحويلة: ۲۳۱۷<br />الهاتف المجاني: ۸۰۰۲٤۹۰۰۰۰ o<br />npc.drug@sfda.gov.sa : بريد إلكتروني o<br />www.sfda.gov.sa/npc : الموقع الالكتروني o<br />&bull; دول الخليج الأخرى:<br />- الرجاء الاتصال بالمؤسسات و الهيئات الوطنية في كل دولة.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            .۲۰۱٥/ تم مراجعة هذه النشرة في ۰٥
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gabex™ 300 mg capsules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each hard gelatin capsule contains 300 mg Pregabalin
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard gelatin capsule
Dark brown opaque cap and white opaque body, printed with 'Jamjoom` on cap and 'PGN 300' on
body in black, size '0' hard gelatin capsule, filled with white to off white homogenous powder.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Neuropathic pain<br />Gabex is indicated for the treatment of peripheral and central neuropathic pain in<br />adults.<br />Epilepsy<br />Gabex is indicated as adjunctive therapy in adults with partial seizures with or without<br />secondary generalization.<br />Generalized Anxiety Disorder<br />Gabex is indicated for the treatment of Generalized Anxiety Disorder (GAD) in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />The dose range is 150 to 600 mg per day given in either two or three divided doses.<br />Neuropathic pain<br />Pregabalin treatment can be started at a dose of 150 mg per day given as two or three<br />divided doses. Based on individual patient response and tolerability, the dose may be<br />increased to 300 mg per day after an interval of 3 to 7 days, and if needed, to a maximum<br />dose of 600 mg per day after an additional 7-day interval.</p><p>Epilepsy<br />Pregabalin treatment can be started with a dose o f 150 m g per day given a s two or three<br />divided doses. Based on individual patient response and tolerability, the dose may be<br />increased to 300 mg per day after 1 week. The maximum dose of 600 mg per day may be<br />achieved after an additional week.<br />Generalised Anxiety Disorder<br />The dose range is 150 to 600 m g per day given as t w o or three divided doses.<br />The need for treatment should be reassessed regularly.<br />Pregabalin treatment can be started with a dose of 150 mg per day. Based on individual<br />patient response and tolerability, the dose may be increased to 300 mg per day after 1<br />week. Following an additional week the dose may be increased to 450 mg per day. The<br />maximum dose of 600 mg per day may be achieved after an additional week.<br />Discontinuation of Pregabalin<br />In a c c o r d a n c e with current clinical practice, if Pregabalin h a s to be discontinued it is<br />recommended this should be done gradually over a minimum o f 1 week independent<br />of the indication.<br />Patients with renal impairment<br />Pregabalin i s eliminated from the systemic circulation primarily by r e n a l excretion<br />as unchanged drug. As Pregabalin clearance is directly proportional to creatinine<br />clearance, dose reduction in patients with compromised renal function must b e<br />individualized according to Creatinine Clearance (CLcr), as indicated in Table1<br />determined using the following formula:<br /><img src="data:image/png;base64,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" alt="" width="700" height="172" vspace="0" hspace="0" border="0" style="width:700px;height:172px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>Pregabalin is removed effectively from plasma by haemodialysis (50% of drug in 4&nbsp;hours). For patients receiving haemodialysis, the Pregabalin daily dose should be adjusted based on renal function.<br />In addition to the daily dose, a supplementary dose should be g i v e n immediately&nbsp;following every 4-hour haemodialysis treatment.</p><p><img src="data:image/png;base64,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" alt="" width="832" height="488" vspace="0" hspace="0" border="0" style="width:832px;height:488px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" />+ Supplementary dose is a single additional dose<br />Patients with hepatic impairment<br />No dose adjustment is required for patients with hepatic impairment.<br />Paediatric population<br />The safety and efficacy of Gabex in children below the age of 12 years and in adolescents<br />(12-17 years of age) have not been established. No data are available.<br />Elderlv (over 65 vears ofage) population<br />Elderly patients may require a dose reduction of Pregabalin due to a decreased renal function<br />(See patients with renal impairment).<br />Method of administration<br />Gabex&trade; may be taken with or without food. Gabex&trade; is for oral use only.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Diabetic patients<br />In accordance with current clinical practice, some diabetic patients who gain weight on<br />Pregabalin treatment may need to adjust hypoglycaemic medicinal products.<br />Hypersensitivity reactions<br />There have been reports in the postmarketing e x p eri e n c e of hypersensitivity r e a c t i o n s ,<br />including cases of angioedema. Pregabalin should be discontinued immediately if symptoms<br />of angioedema, such as facial, perioral, or upper airway swelling occur.<br />Dizziness,somnolence, loss of consciousness, confusion, and mental impairment<br />Pregabalin treatment has been associated with dizziness and somnolence, which could<br />increase the occurrence of accidental injury (fall) in the elderly population. There have also<br />been post-marketing reports of l o s s of c o n s c i o u s n e s s , confusion a n d mental<br />i m p a i r m e n t . Therefore, patients should be advised to exercise caution until they are<br />familiar w i t h the potential effects of the medicinal product.<br />Vision-related effects<br />In controlled trials, a higher proportion of patients treated with P r e g a b a l i n reported blurred<br />vision than did patients treated with placebo which resolved in a majority of cases with<br />continued dosing.<br />In the clinical studies where ophthalmologic testing was conducted, the i n c i d e n c e of visual<br />acuity reduction and visual field changes was greater in Pregabalin-treated patients than in<br />placebo-treated patients; the incidence of fundoscopic changes was greater in placebo-treated<br />patients.<br />In the post-marketing experience, visual adverse reactions have also been reported, including<br />loss of vision, visual blurring or other changes of visual acuity, many of which were transient.<br />Discontinuation o f Pregabalin may result in resolution o r improvement of these visual<br />symptoms.<br />Renal failure<br />Cases of renal failure have been reported and in some cases discontinuation of Pregabalin did<br />show reversibility of this adverse reaction.</p><p>Withdrawal of concomitant antiepileptic medicinal products<br />There are insufficient data for the withdrawal of concomitant antiepileptic medicinal products,<br />once seizure control with Pregabalin in the add-on situation has been reached, in order to reach<br />monotherapy on Pregabalin.<br />Withdrawal symptoms<br />After discontinuation of short-term and long-term treatment with Pregabalin w i t h d r a w a l<br />symptoms have been observed in some patients. The following events have been mentioned:<br />insomnia, headache, nausea, anxiety, diarrhea, flu syndrome, nervousness, depression, pain,<br />convulsion, hyperhidrosis and dizziness, suggestive of physical dependence. The patient should<br />be informed about this at the start of the treatment.<br />Convulsions, including status epilepticus and grand mal convulsions, may occur during<br />Pregabalin use or shortly after discontinuing Pregabalin.<br />Concerning d i s c o n t i n u a t i o n of long-term t r e a t m e n t of Pregabalin, d at a suggest<br />that the incidence and severity of withdrawal symptoms may be dose-related.<br />Con gestive heart failure<br />There have been post-marketing reports of congestive heart failure in some patients receiving<br />Pregabalin. These reactions are m o s t l y seen in elderly c a r d i o v a s c u l a r compromised<br />patients during Pregabalin treatment for a neuropathic i n d i c a t i o n . Pregabalin should be<br />used with caution in these patients. Discontinuation of Pregabalin may resolve the reaction.<br />Treatment of central neuropathic pain dueto spinal cord injury<br />In the treatment of central neuropathic pain due to spinal cord injury the incidence of adverse<br />reactions in general, central nervous system adverse reactions and especially somnolence was<br />increased.<br />This may be attributed to an additive effect due to concomitant medicinal products (e.g. antispasticity<br />agents) needed for this condition. This should be considered when prescribing<br />Pregabalin in this condition.<br />Suicidal ideation and behaviour<br />Suicidal ideation and behavior have been reported in patients treated with anti-epileptic agents in<br />several indications. A meta-analysis of randomized placebo controlled studies of antiepileptic<br />drugs has also shown a small increased risk of suicidal ideation and behavior. The<br />mechanism of this risk is not known and the available data do not exclude the possibility of an<br />increased risk for Pregabalin.<br />Therefore patients should be monitored for signs of suicidal ideation a n d behaviors and<br />appropriate treatment should be considered. Patients (and caregivers of patients) should be<br />advised to seek medical advice should signs of suicidal ideation or behavior emerge.&nbsp;</p><p>Reduced lower gastrointestinal tract function<br />There are post-marketing r e p o r t s of events related to reduced lower gastrointestinal tract<br />function (e.g., intestinal obstruction, paralytic ileus, constipation) when Pregabalin was coadministered<br />with medications that have the potential to produce constipation, such as opioid<br />analgesics.<br />When Pregabalin and opioids will be used in com bination, measures to prevent constipation<br />may be considered (especially in female patients and elderly).<br />Misuse, abuse potential or dependence<br />Cases of misuse, abuse and dependence have been reported. Caution should be exercised in<br />patients with a history of substance abuse and the patient should be monitored for symptoms of<br />Pregabalin misuse, abuse or dependence (development of tolerance, dose escalation. drugseeking<br />behavior have been reported).<br />Encephalopathy<br />Cases of encephalopathy have been reported, mostly in patients with underlying conditions that<br />may precipitate encephalopathy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Since Pregabalin is predominantly e x c r e t e d unchanged in the urine, undergoes negligible<br />metabolism in humans (&lt;2% of a dose recovered in urine as metabolites), does not inhibit drug<br />metabolism in vitro, and is not bound to plasma proteins, it is unlikely to produce, or be subject<br />to, pharmacokinetic interactions.<br />In vivo studies and population pharmacokinetic analysis<br />Accordingly, in in - vivo studies no clinically relevant pharmacokinetic interactions were<br />observed between Pregabalin and Phenytoin, Carbamazepine, Valproic acid, Lamotrigine,<br />Gabapentin, Lorazepam, Oxycodone or Ethanol. Population pharmacokinetic analysis<br />indicated that oral anti diabetics, diuretics, insulin, Phenobarbital, Tiagabine andTopiramate<br />had no clinically significant effect on Pregabalin clearance.<br />Oral contraceptives, norethisterone and/or ethinvl oestradiol<br />Co-administration of Pregabalin with the oral contraceptives norethisterone and/or ethiny1<br />oestradiol does not influence the steady-state pharmacokinetics of either substance.</p><p>CNS influencing medical products<br />Pregabalin may potentiate the effects of ethanol and lorazepam. In controlled clinical trials,<br />multiple oral doses of Pregabalin co-administered with oxycodone, lorazepam, or ethanol did<br />not result in clinically important effects on respiration. In the postmarketing experience, there<br />are reports of respiratory failure and coma in patients taking Pregabalin and other CNS<br />depressant medicinal products. Pregabalin appears to be additive in the impairment of<br />cognitive and gross motor function caused by oxycodone.<br />Interactions and the elderlv<br />No specific p h arm aco d yn am i c interaction studies were conducted in elderly volunteers.<br />Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Women of childbearing potential I Contraception inmales and females<br />As the potential risk for humans is unknown, effective contraception must be used in women of<br />child bearing potential.<br />Pregnancy<br />Pregnancy Category C<br />There are no adequate data from the use of Pregabalin in pregnant women.<br />Studies in animals have shown reproductive toxicity (see 5.3). The potential risk for humans is<br />unknown.<br />Gabex&trade; should not be used during pregnancy unless clearly necessary (if the benefit to the<br />mother clearly outweighs the potential risk to the fetus).<br />Breast-feeding<br />It is not known if Pregabalin is excreted in the breast milk of humans; however, it is present in<br />the milk o f rats. Therefore, breast-feeding is not recommended d u r i n g treatment w i t h<br />Pregabalin.<br />Fertilitv<br />There are no clinical data on the effects of Pregabalin on female fertility.<br />In a clinical trial to assess the effect of Pregabalin on sperm motility, healthy male subjects were<br />exposed to Pregabalin at a dose of 600 mg/day. After 3 months of treatment, there were no<br />effects on sperm motility.<br />A fertility study in female rats has shown adverse reproductive effects. Fertility studies in male<br />Rats have shown adverse reproductive and developmental effects. The clinical relevance of these<br />findings is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Gabex&trade; may have minor or moderate influence on the ability to drive a n d use machines.<br />Gabex&trade; may cause dizziness and somnolence and therefore may influence the ability to<br />drive or use machines. Patients are advised not to drive, operate complex machinery or<br />engage in other potentially hazardous activities until it is known whether this medicinal<br />product affects their ability to perform these activities.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The Pregabalin clinical programme involved over 8900 patients w ho were exposed to<br />Pregabalin, of who over 5600 were in double- blind placebo controlled trials. The most<br />commonly reported adverse reactions were dizziness and somnolence. Adverse reactions were<br />usually mild to moderate in intensity. In all controlled studies, the discontinuation rate due to<br />adverse reactions was 12% for patients receiving Pregabalin and 5% for patients receiving<br />placebo. The most common adverse reactions re suiting in discontinuation from Pregabalin<br />treatment groups were dizziness and somnolence.<br />In the table below all adverse r e a c t i o n s , which occurred at an incidence greater than<br />placebo and in more than one patient, are listed by class and frequency (very common ( &ge;1/10);<br />common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to&lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very<br />rare (&lt;1/10,000), not known (cannot be estimated from the available data).<br />Within each frequency grouping, undesirable effects are presented in order of decreasing<br />seriousness.<br />The adverse reactions listed may also be associated with the underlying disease and/or<br />concomitant medicinal products.<br />In the treatment of central neuropathic pain due to spinal cord injury the incidence of<br />Adverse reactions in general, CNS adverse reactions and especially somnolence was increased<br />Additional reactions reported from post-marketing experience are included in italics in the list<br />below.</p><p>Additional reactions reported from post-marketing experience are included in italics in the list below.</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse drug reactions</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Nasopharyngitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Neutropenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p><em>Hypersensitivity</em></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p><em>Angioedema, allergic reaction</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Appetite increased</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Anorexia, hypoglycaemia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Psychiatric disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Euphoric mood, confusion, irritability, disorientation, insomnia, libido decreased</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hallucination, panic attack, restlessness, agitation, depression, depressed mood, elevated mood, <em>aggression</em>, mood swings, depersonalisation, word finding difficulty, abnormal dreams, libido increased, anorgasmia, apathy</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Disinhibition</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Dizziness, somnolence, headache</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Ataxia, coordination abnormal, tremor, dysarthria, amnesia, memory impairment, disturbance in attention, paraesthesia, hypoaesthesia, sedation, balance disorder, lethargy</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Syncope, stupor, myoclonus, <em>loss of consciousness</em>, psychomotor hyperactivity, dyskinesia, dizziness postural, intention tremor, nystagmus, cognitive disorder, <em>mental impairment</em>, speech disorder, hyporeflexia, hyperaesthesia, burning sensation, ageusia, <em>malaise</em></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p><em>Convulsions</em>, parosmia, hypokinesia, dysgraphia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Vision blurred, diplopia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Peripheral vision loss, visual disturbance, eye swelling, visual field defect, visual acuity reduced, eye pain, asthenopia, photopsia, dry eye, lacrimation increased, eye irritation</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p><em>Vision loss, keratitis</em>, oscillopsia, altered visual depth perception, mydriasis, strabismus, visual brightness</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Ear and labyrinth disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Vertigo</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hyperacusis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Tachycardia, atrioventricular block first degree, sinus bradycardia, <em>congestive heart failure</em></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p><em>QT prolongation</em>, sinus tachycardia, sinus arrhythmia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hypotension, hypertension, hot flushes, flushing, peripheral coldness</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Dyspnoea, epistaxis, cough, nasal congestion, rhinitis, snoring, nasal dryness</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p><em>Pulmonary oedema</em>, throat tightness,</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Vomiting, <em>nausea</em>, constipation, <em>diarrhoea</em>, flatulence, abdominal distension, dry mouth</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Gastrooesophageal reflux disease, salivary hypersecretion, hypoaesthesia oral</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Ascites, pancreatitis, <em>swollen tongue</em>, dysphagia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rash papular, urticaria, hyperhidrosis, <em>pruritus</em></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p><em>Stevens Johnson syndrome,</em> cold sweat</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Muscle cramp, arthralgia, back pain, pain in limb, cervical spasm</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Joint swelling, myalgia, muscle twitching, neck pain, muscle stiffness</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Rhabdomyolysis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Urinary incontinence, dysuria</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Renal failure, oliguria, <em>urinary retention </em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Reproductive system and breast disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Erectile dysfunction</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Sexual dysfunction, ejaculation delayed, dysmenorrhoea, breast pain</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Amenorrhoea, breast discharge, breast enlargement, <em>gynaecomastia</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Oedema peripheral, oedema, gait abnormal, fall, feeling drunk, feeling abnormal, fatigue</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Generalised oedema, <em>face oedema</em>, chest tightness, pain, pyrexia, thirst, chills, asthenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Weight increased</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Blood creatine phosphokinase increased, alanine aminotransferase increased, aspartate aminotransferase increased, blood glucose increased, platelet count decreased, blood creatinine increased, blood potassium decreased, weight decreased</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>White blood cell count decreased</p></td></tr></tbody></table><p>&nbsp;</p><p>After discontinuation of short-term and long-term treatment with Pregabalin withdrawal symptoms have been observed in some patients.</p><p>&nbsp;</p><p>The following reactions have been mentioned: insomnia, headache, nausea, anxiety, diarrhoea, flu syndrome, convulsions, nervousness, depression, pain<strong>,</strong> hyperhidrosis and dizziness, suggestive of physical dependence. The patient should be informed about this at the start of the treatment.</p><p>&nbsp;</p><p>Concerning discontinuation of long-term treatment of Pregabalin, data suggest that the incidence and severity of withdrawal symptoms may be dose-related.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;To report any side effect(s):</strong></p><p><strong>&bull; Saudi Arabia:</strong></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><ul><li>Fax: +966-11-205-7662</li><li>Call NPC at +966-11-2038222,</li></ul><p>Exts: 2317-2356-2353-2354-2334-2340.</p><ul><li>Toll free phone: 8002490000</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: <u>www.sfda.gov.sa/npc</u></li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the post-marketing experience, the most commonly reported adverse reactions<br />observed when Pregabalin was taken in overdose included somnolence, confusional state,<br />agitation and restlessness. In rare occasions, cases of coma have been reported.<br />Treatment of Pregabalin overdose should include general supportive measures and may<br />include haemodialysis if necessary.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antiepileptics, other antiepileptics ATC code:<br />N03AX16<br />The active substance, Pregabalin, is a gamma-aminobutyric acid analogue ((S)-3-<br />(aminomethyl)-5-methylhexanoic acid).<br />Mechanism of action<br />Pregabalin binds to an auxiliary subunit (&alpha;2- &delta; protein) of voltage-gated calcium channels in<br />the central nervous system,</p><p>Clinical Efficacy and safety<br />Neuropathic pain<br />Efficacy has been shown in trials in diabetic neuropathy, p o s t herpetic neuralgia and<br />spinal cord injury. Efficacy has not been studied in other models of neuropathic pain.<br />Pregabalin has been studied in 10 controlled clinical trials of up to 13 weeks with twice a<br />day dosing (BID) and up to 8 weeks with three times a day (TID) dosing. Overall, the safety<br />and efficacy profiles for BID and TID dosing regimens were similar.<br />In clinical trials up to 12 weeks for both peripheral and central nemopathic pain, a reduction<br />in pain was seen by week 1 and was maintained throughout the treatment period.<br />In controlled clinical trials in peripheral neuropathic pain 35% o f the Pregabalin treated<br />patients and 18% of the patients on placebo had a 50% improvement in pain score.<br />For patients not experiencing somnolence, such an improvement was observed in 33% of<br />patients treated with Pregabalin and 18% of patients on placebo. For patients<br />who experienced somnolence t h e responder rates were 48% on Pregabalin and<br />16% on placebo.<br />In the controlled clinical trial in central neuropathic pain 22% of the Pregabalin treated<br />patients and 7% of the patients on placebo had a 50% improvement in pain score.</p><p>Epilepsy<br />Adjunctive Treatment<br />Pregabalin has been studied in 3 controlled clinical trials of 12 week duration with either<br />twice a day dosing (BID) or three times a day (TID) dosing. Overall, the safety and efficacy<br />profiles for BID and TID dosing regimens were similar.<br />A reduction in seizure frequency was observed by Week.<br />Monotherapy (newly diagnosed patients)<br />Pregabalin has been studied in 1 controlled clinical trial of 56 week duration with twice a<br />day dosing (BID). Pregabalin did not achieve non-inferiority to lamotrigine based on the 6-<br />month seizure freedom endpoint. Pregabalin and lamotrigine were similarly safe and well<br />tolerated.<br />Generalized Anxiety Disorder<br />Pregabalin has been studied in 6 controlled trials of 4-6 week duration, an elderly study of<br />8 week duration and a long-term relapse prevention study with a double blind relapse<br />prevention phase of 6 months duration.<br />Relief of the symptoms of GAD as reflected by the Hamilton Anxiety Rating Scale<br />(HAM- A) was observed by Week 1.<br />In controlled clinical trials (4-8 week duration) 52% of the Pregabalin treated patients and<br />38% of the patients on placebo had at least a 50% improvement in HAM-A total score from<br />baseline to endpoint.<br />In controlled trials, a higher proportion of patients treated with Pregabalin reported blurred<br />vision than did patients treated with placebo which resolved in a majority of cases with<br />continued dosing. Ophthamologic testing (including visual acuity testing, formal visual<br />field testing and dilated funduscopic examination) was conducted in over 3600 patients<br />within controlled clinical trials.<br />In these patients, visual acuity was reduced in 6.5% of patients treated with Pregabalin,<br />and 4.8% of placebo-treated patients. Visual field changes were detected in 12.4% of<br />P r e g a b a l i n treated, and 11.7% of placebo-treated patients. Funduscopic changes were<br />observed in 1.7% of Pregabalin-treated and 2.1% of placebo-treated patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregabalin steady-state pharmacokinetics are similar in healthy volunteers, patients with<br />epilepsy receiving anti-epileptic drugs and patients with chronic pain.<br />Absorption<br />Pregabalin is rapidly absorbed when administered in the fasted state, with peak plasma<br />concentrations occurring within 1 hour following both single and multiple dose<br />administration.<br />Pregabalin oral bioavailability is estimated to be &ge;90% and is independent o f dose.<br />Following repeated administration, steady state is achieved within 24 to 48 hours. The rate<br />of Pregabalin absorption is decreased when given with food resulting in a decrease in Cmax<br />by approximately<br />25-30% and a delay in t max to approximately 2.5 hours. However, administration of<br />Pregabalin with food has no clinically significant effect on the extent of Pregabalin<br />absorption.<br />Distribution<br />In preclinical studies, Pregabalin has been shown to cross the blood brain barrier in mice,<br />rats, and monkeys. Pregabalin has been shown to cross the placenta in rats and is present in<br />the milk of lactating rats. In humans, the apparent volume of distribution of Pregabalin<br />following oral administration is approximately 0.561/kg. Pregabalin is not bound to plasma<br />proteins.<br />Biotransformation<br />Pregabalin undergoes negligible metabolism in humans. Following a dose of radiolabelled<br />Pregabalin, approximately 9 8 % of t h e radio activity recovered in t h e urine was<br />unchanged Pregabalin.<br />The N-methylated derivative of Pregabalin, the major metabolite of Pregabalin found in<br />urine, accounted for 0.9% of the dose. In preclinical studies, there was no indication of<br />racemisation of Pregabalin S-enantiomer to the R-enantiomer.</p><p>Elimination<br />Pregabalin is eliminated from the systemic circulation primarily by renal excretion as<br />unchanged drug.<br />Pregabalin mean elimination half-life is 6.3 hours. Pregabalin plasma c l e a r a n c e and renal<br />clearance are directly proportional to creatinine clearance.<br />Dose a d j u s t m e n t i n patients with reduced renal function o r undergoing haemodialysis<br />is necessary.<br />Linearity/non-linearity<br />Pregabalin pharmacokinetics is linear over the recommended daily dose range. Inter-subject<br />pharmacokinetic variability for Pregabalin is low (&lt;20%). Multiple dose pharmacokinetics<br />is predictable from single-dose data. Therefore, there is no need for routine monitoring of<br />plasma concentrations of Pregabalin.<br />Gender<br />Clinical trials indicate that gender does not have a clinically significant influence on the<br />plasma concentrations of Pregabalin.<br />Renal impairment<br />Pregabalin clearance is directly proportional to creatinine clearance. In addition, Pregabalin<br />is effectively removed from plasma by haemodialysis (following 4 hour haemodialysis<br />treatment plasma Pregabalin concentrations are reduced by approximately 50%). Because<br />renal elimination is the major elimination pathway, dose reduction in patients with renal<br />impairment and dose supplementation following haemodialysis is necessary<br />Hepatic impairment<br />No specific pharmacokinetic studies were carried out in patients with impaired<br />liver function. Since Pregabalin does not undergo significant metabolism and is<br />excreted predominantly a s unchanged drug in the urine, impaired liver function<br />would not be expected to significantly alter Pregabalin plasma concentrations.</p><p>Elderly (over 65 years of age)<br />Pregabalin clearance tends to decrease with increasing age. This decrease in Pregabalin oral<br />clearance is consistent with decreases in creatinine clearance associated with increasing age.<br />Reduction of Pregabalin dose may be required in patients who have age related compromised<br />renal function.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In conventional safety pharmacology studies in animals, Pregabalin was well-tolerated at<br />clinically relevant doses. In repeated dose toxicity studies in rats and monkeys CNS effects<br />were observed, including hypoactivity, hyperactivity and ataxia. An increased incidence of<br />retinal atrophy commonly observed in aged albino rats was seen after long term exposure to<br />Pregabalin at exposures5 times the mean human exposure at the maximum recommended<br />clinical dose.<br />Pregabalin was not teratogenic in mice, rats or rabbits. Foetal toxicity in rats and rabbits<br />occurred only at exposures sufficiently above human exposure. In prenatal/postnatal toxicity<br />studies, Pregabalin induced offspring developmental toxicity in rats at exposures &gt;2 times the<br />maximum recommended human exposure.<br />Adverse effects on fertility in male and female rats were only observed at exposures sufficiently<br />in excess of therapeutic exposure. Adverse effects on male reproductive organs and sperm<br />parameters were reversible and occurred only at exposures sufficiently in excess of therapeutic<br />exposure or were associated with spontaneous degenerative processes in male reproductive<br />organs in the rat. Therefore the effects were considered of little or no clinical relevance.<br />Pregabalin is not genotoxic based on results of a battery of in vitro and in vivo tests.<br />Two-year carcinogenicity studies with Pregabalin were conducted in rats and mice. No tumors<br />were observed in rats at exposures up to 24 times the mean human exposure at the maximum<br />recommended clinical dose of 600 mg/day. In mice, no increased incidence of tumors was<br />found at exposures similar to them in human exposure, but an increased incidence of<br />haemangiosarcoma was observed at higher exposures. The non-genotoxic mechanism of<br />Pregabalin-induced t u m o u r f o r m a t i o n i n mice i n v o l v e s platelet changes and associated<br />endothelial cell proliferation. These platelet changes were not present in rats or in humans based<br />on short term and limited long term clinical data. There is no evidence to suggest an associated<br />risk to humans.<br />In juvenile rats the types of toxicity do not differ qualitatively from those observed in adult rats.<br />However, juvenile rats are more sensitive. At therapeutic exposures, there was evidence of CNS<br />clinical signs of hyperactivity and bruxism and some changes in growth (transient body weight<br />gain suppression). Effects on the oestrus cycle were observed at 5-fold the human therapeutic&nbsp;exposure. Reduced acoustic startle response was observed in juvenile rats 1-2 weeks<br />after exposure at &gt;2 times the human therapeutic exposure. Nine weeks after exposure,<br />this effect was no longer observable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregelatinized starch, Talc, and Gelatin that containsSodium lauryl sulphate and<br />Titanium dioxide. Gabex&trade; 300mg capsules also contain iron oxide red.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of the reach and sight of children.<br />Do not store above 30 &deg;C.<br />Store in the original package.<br />Store in dry place.<br />Do not use this medicine after the expiry date which is stated on the carton.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregabalin 300 mg capsules are packed as Aluminium-PVC/PVDC blisters containing 30 (3x10)<br />hard capsules in outer carton with Patient Information Leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist<br />how to dispose of medicines no longer required. These measures will help to protect the<br />environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Company Limited
Plot No. ME1:3, Phase V, Industrial City, P.O. Box 6267, Jeddah-
21442, Kingdom of Saudi Arabia.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jun 2015
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>